Patriot Act and PSE

Executive Summary

Provisions requiring behind-the-counter placement of products containing pseudoephedrine have been added to the final version of the conference report for the Patriot Act reauthorization package. The report was filed Dec. 8 and will be considered by the House and Senate during the week of Dec. 12, House Judiciary Committee Chairman James Sensenbrenner (R-Wis.), announces. The provision for BTC sale was first added to the draft version of the conference report in November (1"The Tan Sheet" Nov. 28, 2005, p. 3). Also added at that time were essentially all elements of the Talent/Feinstein Combat Meth Act (S 103), except for the provision requiring Schedule V status for pseudoephedrine. The conference report's final version contains a new pseudoephedrine sales limit of 9 g/30 days...